Future challenges in the clinical development of thymidylate synthase inhibitor compounds

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Thymidylate synthase (TS) is crucial for DNA synthesis and a key target in cancer therapy.
• Fluoropyrimidines were the first agents targeting TS, leading to the development of new antifolate analogues.
• Malignant cell proliferation increases metabolic demands, highlighting TS as a critical therapeutic target.

Purpose of the Study:

• To provide an update on the current status of thymidylate synthase inhibitor compounds.
• To discuss future challenges in the clinical development of TS inhibitors.
• To identify factors influencing the antitumor activity and therapeutic selectivity of TS inhibitors.

Main Methods:

• Review of preclinical and clinical investigations of TS inhibitor compounds.
• Analysis of data from early clinical studies on various antifolate analogues.
• Discussion of challenges in clinical development and therapeutic selectivity.

Main Results:

• Several new antifolate analogues targeting TS have been developed, including ZD1694, LY231514, BW1843U89, ZD9331, AG331, and AG337.
• Preclinical and early clinical data suggest varying antitumor activity spectra for these analogues.
• Each analogue inhibits TS but may exhibit different efficacy across tumor types.

Conclusions:

• Antifolate analogues targeting thymidylate synthase represent a promising class of anticancer agents.
• Identifying critical factors for antitumor activity and therapeutic selectivity is essential for future clinical development.
• Further research is needed to optimize the use of these TS inhibitors in cancer therapy.